Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 5/20 | 0.55 |
| ▸ | ACVRL1 | P37023 | 5/20 | 0.55 |
| ▸ | RET | P07949 | 2/20 | 0.44 |
| ▸ | ROS1 | P08922 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 12/20 | 0.44 |
| ▸ | IGF1R | P08069 | 11/20 | 0.44 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.38 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL768094 | 0.93 | NTRK1 (0.55) | NTRK1ACVRL1RETROS1CYP3A4 | |
| SCHEMBL439782 | 0.86 | NTRK1 (0.64) | NTRK1ACVRL1RETROS1CYP3A4 | |
| Hydrochloric Acid SCHEMBL767126 | 0.86 | NTRK1 (0.63) | NTRK1ACVRL1RETROS1CYP3A4 | |
| SCHEMBL469135 | 0.84 | NTRK1 (0.60) | NTRK1ACVRL1RETROS1CYP3A4 | |
| Hydrochloric Acid SCHEMBL768247 | 0.81 | NTRK1 (0.62) | NTRK1ACVRL1RETROS1CYP3A4 | |
| SCHEMBL14301007 | 0.81 | NTRK1 (0.57) | NTRK1ACVRL1RETROS1CYP3A4 | |
| SCHEMBL772905 | 0.80 | NTRK1 (0.49) | NTRK1ACVRL1RETROS1CYP3A4 | |
| SCHEMBL10283941 | 0.79 | NTRK1 (0.52) | NTRK1ACVRL1CYP3A4IGF1R | |
| SCHEMBL768139 | 0.79 | NTRK1 (0.52) | NTRK1ACVRL1CYP3A4IGF1R | |
| SCHEMBL14719441 | 0.79 | NTRK1 (0.64) | NTRK1ACVRL1RETROS1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | NTRK1 718/4885ACVRL1 3502/4885RET 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.